NASDAQ:BASI - Bioanalytical Systems Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.00 -0.02 (-0.99 %) (As of 05/24/2019 08:00 AM ET)Previous Close$2.02Today's Range$1.98 - $2.0352-Week Range$1.18 - $2.59Volume500 shsAverage Volume18,834 shsMarket Capitalization$20.58 millionP/E RatioN/ADividend YieldN/ABeta0.91 ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana. Receive BASI News and Ratings via Email Sign-up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BASI Previous Symbol CUSIPN/A CIK720154 Webhttp://www.basinc.com/ Phone765-463-4527Debt Debt-to-Equity Ratio0.91 Current Ratio0.63 Quick Ratio0.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.35 million Price / Sales0.78 Cash Flow$0.2139 per share Price / Cash Flow9.35 Book Value$1.00 per share Price / Book2.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-190,000.00 Net Margins-2.82% Return on Equity-3.12% Return on Assets-1.09%Miscellaneous Employees224 Outstanding Shares10,291,000Market Cap$20.58 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions What is Bioanalytical Systems' stock symbol? Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI." How were Bioanalytical Systems' earnings last quarter? Bioanalytical Systems, Inc. (NASDAQ:BASI) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company earned $9.34 million during the quarter. Bioanalytical Systems had a negative return on equity of 3.12% and a negative net margin of 2.82%. View Bioanalytical Systems' Earnings History. When is Bioanalytical Systems' next earnings date? Bioanalytical Systems is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Bioanalytical Systems. Has Bioanalytical Systems been receiving favorable news coverage? Media coverage about BASI stock has trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bioanalytical Systems earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Bioanalytical Systems' key competitors? Some companies that are related to Bioanalytical Systems include Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), National Research (NRCIB), National Research (NRCIA), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY). What other stocks do shareholders of Bioanalytical Systems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioanalytical Systems investors own include Athersys (ATHX), Idera Pharmaceuticals (IDRA), GASTAR EXPL INC/SH (GST), Novavax (NVAX), Tenax Therapeutics (TENX), ZIOPHARM Oncology (ZIOP), SLS International (SLS), Agenus (AGEN), Celsion (CLSN) and Conatus Pharmaceuticals (CNAT). Who are Bioanalytical Systems' key executives? Bioanalytical Systems' management team includes the folowing people: Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 49)Ms. Jill C. Blumhoff, CFO, VP of Fin. & Sec. (Age 43)Mr. Robert Leasure Jr., Pres, CEO & Director (Age 59)Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 74)Mr. D. Thomas Oakley, Chief Operating Officer Who are Bioanalytical Systems' major shareholders? Bioanalytical Systems' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.28%). Company insiders that own Bioanalytical Systems stock include Daniel Thomas Oakley, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff and Robert Jr Leasure. View Institutional Ownership Trends for Bioanalytical Systems. Which institutional investors are buying Bioanalytical Systems stock? BASI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Bioanalytical Systems stock in the last two years include Daniel Thomas Oakley, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff and Robert Jr Leasure. View Insider Buying and Selling for Bioanalytical Systems. How do I buy shares of Bioanalytical Systems? Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bioanalytical Systems' stock price today? One share of BASI stock can currently be purchased for approximately $2.00. How big of a company is Bioanalytical Systems? Bioanalytical Systems has a market capitalization of $20.58 million and generates $26.35 million in revenue each year. Bioanalytical Systems employs 224 workers across the globe. What is Bioanalytical Systems' official website? The official website for Bioanalytical Systems is http://www.basinc.com/. How can I contact Bioanalytical Systems? Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected] MarketBeat Community Rating for Bioanalytical Systems (NASDAQ BASI)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 96 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 213MarketBeat's community ratings are surveys of what our community members think about Bioanalytical Systems and other stocks. Vote "Outperform" if you believe BASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BASI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Leveraged Buyout (LBO) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.